Warning on risks: Financial contracts for difference are complex instruments and are associated with a high risk of rapid financial losses due to leverage. On 76.44% of retail investor accounts, financial losses occur when trading financial contracts for difference with this provider. You should consider whether you understand how financial contracts for difference work, and whether you can afford to take the high risk of suffering financial losses. Please read the Risk Disclosures.

Logo icon

Market analysis and news

Get an overview of current market developments with regular analysis from our analysts. We offer a detailed view of key events, economic indicators and investment opportunities. Follow the development of the markets with us and make decisions based on data and experience.

Group 3122
Group 3373
Study

How We Went From Savers to Investors

35 Years Since the Beginning of Voucher Privatization in Czechoslovakia
Scott Graham OQMZwNd3ThU Unsplash
9/2/2024
MiCA: A new era of cryptocurrencies in Europe
MiCA (Markets in Crypto Assets) regulation is a revolutionary step for European cryptoassets markets, bringing new opportunities and better security to this dynamic and fast-growing sector. For the European Union, it is a ticket to a new era in the digital financial world. This 150-page legal framework builds on similar EU rules for securities trading. Any company wishing to offer cryptocurrency asset services in the EU will have to obtain authorisation from one of the 27 national EU financial regulators.1
Babak Habibi 34uOaL1He4w Unsplash
31/1/2024
Samsung has traded Google for its competition. Galaxy S24 will have Baidu's AI under the casing
Chinese tech giant Baidu will partner with Samsung to integrate the functionality of its chatbot Ernie into Galaxy S24 smartphones in China. This report comes as a big surprise as most of Samsung's smartphones in other countries use technology from the rival company Google, which is under Alphabet's umbrella.
Roberto Sorin RS0 H PyByk Unsplash
23/1/2024
Sanofi to cure rare diseases, buys patent for 2.2 billion
French pharmaceutical company Sanofi has agreed to buy the INBRX-101 drug development project from Inhibrx Inc. It is opening a new account for about $2.2 billion in a bid to boost its rare disease business. The acquisition is in line with the company's portfolio growth strategy and complements Sanofi's 30-year heritage in rare diseases as well as its industry leadership in immunology and inflammation.
Johnyvino R54V69BN0MI Unsplash
16/1/2024
Microsoft enters into a partnership with Vodafone
The British company is investing $1.5 billion in customer-focused artificial intelligence developed using Azure technologies OpenAI and Copilot from Microsoft. Since the investment, it promises to replace physical data centers with cheaper and scalable Azure cloud services.Vodafone and Microsoft have agreed a 10-year partnership to bring generative AI, digital, enterprise and cloud services to more than 300 million businesses and consumers in their European and African markets.

Latest analyses